DOJ Reaches Settlement With Blackstone’s LivCor Over Alleged Rent Price-Fixing 
Nvidia and Groq Strike Strategic AI Inference Licensing Deal 
BlackRock-Backed Global Ports Deal Faces Uncertainty Amid Cosco Demands 
Vietnam’s EV Taxi Giant GSM Eyes Hong Kong IPO With $2–3 Billion Valuation 
Winter Storm Devin Triggers Massive Flight Cancellations and Travel Disruptions Across the U.S. 
Brazilian Oil Workers’ Strike Continues as Key Petrobras Union Rejects Proposal 
Lloyds Banking Group to Close Invoice Factoring Business by End of 2025 
Warner Bros. Discovery Shares Slide Amid Report of Potential Paramount Skydance Lawsuit 
BP Nears $10 Billion Castrol Stake Sale to Stonepeak 
Winter Storm Disrupts Northeast Travel as Snow and Ice Blanket New York, New Jersey 
China’s LandSpace Takes Aim at SpaceX With Reusable Rocket Ambitions 
Star Entertainment Leadership Shake-Up Deepens as CFO and COO Exit Amid Ongoing Restructuring 
TSMC Honors Japanese Chip Equipment Makers With 2025 Supplier Awards 
BP’s Castrol Stake Sale Raises Debt Relief Hopes but Sparks Cash Flow Concerns 
Trump Administration Probes Corporate DEI Programs, Raising Questions for Google Stock 
L&F Tesla Battery Supply Deal Value Drops Sharply Amid EV Market Slowdown 
Nike Stock Jumps After Apple CEO Tim Cook Buys $2.9M Worth of Shares 
NEW YORK, Feb. 21, 2017 -- MYnd Analytics, Inc. (OTCQB:MYAN), a predictive medicine company which brings objective physical findings to psychiatric treatment in order to reduce trial and error treatment in mental health, announced that Dr. Robin Smith, Chairman of the Board of MYnd Analytics, Inc. will give the Company’s presentation at the Small Cap Nation Family Office and Life Science Symposium at the NASDAQ market site at Times Square at 3:55pm today. Dr. Smith will be discussing the emergence of new technologies and the Company’s predictive analytic tool that can assists physicians in reducing trial and error prescribing of medications in mental health.
The latest clinical results showed patients of physicians that utilized the MYnd recommendations to make treatment decisions had a 144% improvement in depression scores and a 75% greater reduction in suicidality. Finally, treatments which followed the MYnd recommendations resulted in 2.5 time’s greater adherence to therapy.
MYnd has been designated an Emerging Technology by United Healthcare, permitting limited reimbursement, and has recently received CMS approval in California so that it can bill Medicare and Medicaid as a jump start to commercializing its product in California. The Company is in discussions with large healthcare systems and physician to utilize its tool to improve care, increase compliance, and lower overall healthcare costs.
The company is well positioned to launch its technology globally and is excited to make a huge impact on society https://youtu.be/eWA9XF5nL7I.
About MYnd Analytics, Inc.
MYnd Analytics, Inc. (www.myndanalytics.com) provides a unique set of reference data and analytic tools for clinicians and researchers in psychiatry. While treatment for mental disorders has doubled in the last 20 years, it is estimated that 17 million Americans have failed two or more medication therapies for their mental disorders. The Company’s Psychiatric EEG Evaluation Registry, or PEER Online, is a registry and reporting platform that allows medical professionals to exchange treatment outcome data for patients referenced to objective neurophysiology data obtained through a standard electroencephalogram (EEG). Based on the Company’s original physician-developed database, there are now more than 38,000 outcomes for over 10,000 unique patients in the PEER registry. The goal of PEER Online is to provide objective, personalized data to assist physicians in the selection of appropriate medications.
To read more about the benefits of this patented technology for patients, physicians and payers, please visit www.myndanalytics.com.
About The Family Office Investment Symposium
The Family Office Investment Symposium is an ongoing series that identifies superior transition-stage private and public biotech, life science, healthcare and medical technology companies. These highlighted companies are focused on the latest disruptive technologies and relevant industry trends. The SCN symposiums are designed to connect a curated group of highly vetted companies with a carefully selected group of sophisticated investors.
About Small Cap Nation™
Small Cap Nation (www.smallcapnation.com) is a New York based financial media and content distribution platform that develops and delivers breaking, on-demand news and information from our studios at the New York Stock Exchange, and the NASDAQ MarketSite in Times Square. SCN’s focus is on the multi-billion dollar small cap sector, both domestically and internationally. This video-centric programming is distributed across digital channels including social media, broadcast, and newsletters. SCN’s distribution consists of a proprietary network of more than 5 million active investors, Funds, Institutions and more than 4000 Family Offices through our strategic alliance with Family Office Networks, Cavendish Global and Family Office Insights. Financial news and trading sites that feature SCN’s content include; Harvest Exchange™, Bloomberg, Yahoo Finance, SCN YouTube Channel, StockWatchIndex, FoxBusinessNews, Business Insider, and more.
Contact Paul Buck, CFO MYnd Analytics 949-420-4402 Work 866-867-4446 Fax [email protected]
